ahlam1399
05-30-2015, 06:41 PM
Pfizer?s Ibrance drug slows progression of breast cancer
CHICAGO (Reuters) - A Phase III trial of Pfizer Inc's drug Ibrance showed that, in combination with hormone therapy, the drug more than doubled the duration of disease control for women with the most common type of breast cancer.http://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/46c8cb68/sc/14/mf.gif?resize=1%2C1
http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=kmQeNLhoWiM:LhRN3WN_8Uc:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=kmQeNLhoWiM:LhRN3WN_8Uc:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=kmQeNLhoWiM:LhRN3WN_8Uc:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=kmQeNLhoWiM:LhRN3WN_8Uc:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=kmQeNLhoWiM:LhRN3WN_8Uc:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/kmQeNLhoWiM
CHICAGO (Reuters) - A Phase III trial of Pfizer Inc's drug Ibrance showed that, in combination with hormone therapy, the drug more than doubled the duration of disease control for women with the most common type of breast cancer.http://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/46c8cb68/sc/14/mf.gif?resize=1%2C1
http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=kmQeNLhoWiM:LhRN3WN_8Uc:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=kmQeNLhoWiM:LhRN3WN_8Uc:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=kmQeNLhoWiM:LhRN3WN_8Uc:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=kmQeNLhoWiM:LhRN3WN_8Uc:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=kmQeNLhoWiM:LhRN3WN_8Uc:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/kmQeNLhoWiM